Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Edwards Invests In Mitral, Tricuspid Solutions As TAVR Growth Exceeds Expectations

Executive Summary

Sales of Sapien transcatheter aortic valves grew about 27% year over year in the third quarter of 2019 while revenues from Edwards’ transcatheter mitral and tricuspid therapies grew to almost $10m, led by sales of the Pascal transcatheter mitral repair system in Europe.

You may also be interested in...



Edwards Lifesciences Mike Mussallem To Retire As CEO, Bernard Zovighian Named Successor

Mussallem’s retirement at age 70 does not come as a surprise to the Street, but analysts expect some headwinds for his successor Bernard Zovighian, who has been heading the firm’s transcatheter mitral and tricuspid valve repair business.

Edwards Receives CE Mark For PASCAL Transcatheter Tricuspid Valve Repair System

Edwards Lifesciences received the CE mark for its PASCAL transcatheter system for treating triscupid valve regurgitation, competing against Abbott’s newly CE-marked TriClip. 

Abbott Stays Ahead Of Edwards In Transcatheter Mitral Valve Race With Tendyne CE Mark

Tendyne is indicated for the treatment of significant mitral regurgitation in patients who are not candidates for surgery. It complements Abbott’s MitraClip mitral valve repair device and is an important part of the company’s strategy to be the leading structural heart device company.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel